In vitro differentiation of cGMP-grade retinal pigmented epithelium from human embryonic stem cells

Fernando H. Lojudice1,2†, Rodrigo A. Brant Fernandes1*†, Francesco Innocenti1,2, Carlos E. Franciozi4, Priscila Cristovam1,2, Mauricio Maia1, Mari C. Sogayar2,3 and Rubens Belfort Junior1

Abstract

Background: The World Health Organization (WHO) estimates that the number of individuals who lose their vision due to retinal degeneration is expected to reach 6 million annually in 2020. The retinal degenerative diseases affect the macula, which is responsible for central and detailed vision. Most macular degeneration, i.e., age-related macular degeneration (AMD) develops in the elderly; however, certain hereditary diseases, such as the Stargardt disease, also affect young people. This degeneration begins with loss of retinal pigmented epithelium (RPE) due to formation of drusen (atrophic) or abnormal vessels (exudative). In wet AMD, numerous drugs are available to successful treat the disease; however, no proven therapy currently is available to treat dry AMD or Stargardt. Since its discovery, human embryonic stem cells (hESCs) have been considered a valuable therapeutic tool. Some evidence has shown that transplantation of RPEs differentiated from hESCs cells can result in recovery of both RPE and photoreceptors and prevent visual loss.

Methods: The human embryonic WA-09 stem cell lineage was cultured under current Good Manufacturing Practices (cGMP) conditions using serum-free media and supplements. The colonies were isolated manually and allowed to spontaneously differentiate into RPE cells.

Results: This simple and effective protocol required minimal manipulation and yielded more than 10^8 RPE cells by the end of the differentiation and enrichment processes, with cells exhibiting a cobblestone morphology and displaying cellular markers and a gene expression profile typical of mature RPE cells. Moreover, the differentiated cells displayed phagocytic activity and only a small percentage of the total cells remained positive for the Octamer-binding transcriptions factor 4 (OCT-4) pluripotency cell marker.

Conclusions: These results showed that functional RPE cells can be produced efficiently and suggested the possibility of scaling-up to aim at therapeutic protocols for retinal diseases associated with RPE degeneration.
Background
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness worldwide [1, 2] that has been estimated to affect more than 8 million people in the United States alone. Despite the introduction of new preventive and treatment therapies, the AMD prevalence should increase by 97% by 2050 [3–5].

Outer retinal degenerative diseases, such as AMD, lead to progressive, irreversible loss of the central visual acuity, with the retinal pigmented epithelium (RPE) the focus of the disease pathophysiology. The role of RPEs is elimination of toxic products resulting from the photoreceptors outer segments metabolism, a function that generally decreases with age.

The advanced forms of AMD are neovascular (wet AMD) and non-neovascular atrophic AMD (dry AMD), both of which are associated with visual acuity loss [5].

A break in Bruch’s membrane may open space for the choroidal vessels to grow into the subretinal space, leading to leakage and subretinal scar formation (wet AMD).

AMD develops when the RPE cannot perform its physiologic role and the metabolic waste from the photoreceptors outer segments begins to accumulate in the subretinal space, under Bruch’s membrane (drusen). This leads to decreased permeability of Bruch’s membrane and reduction of the choroidal vasculature, leading to increased accumulation of waste products and subsequent loss of the underlying RPE, which eventually results in deterioration of the corresponding photoreceptors [6].

Despite the robust development of new therapies and drugs for wet AMD, no proven therapy currently is available to treat dry AMD and outer retinal diseases associated with RPE degeneration.

Some evidence has suggested that transplantation of differentiated RPE cells derived from human embryonic stem cells (hESCs) prevents loss of the photoreceptors and vision in models of rodent macular degeneration [7, 8]. In studies using RCS rats, subretinal transplantation of RPEs derived from hESCs resulted in survival of the photoreceptors near the hESC-RPE implantation site compared with other retinal regions, with vision maintained for longer periods of time compared to controls, and no side effects [8]. This and another safety study [7] have suggested that hESCs may be a potentially safe and inexhaustible source of RPEs to effectively treat various degenerative retinal diseases. Recently, one US group and one South Korean group have reported the safety results and possible biologic activity of RPE cells derived from embryonic cells implanted in patients with dry AMD and Stargardt disease [9–12]. A Japanese group also described for the first time the successful implantation of differentiated RPE cells from the patient’s own reprogrammed induced pluripotent stem (iPSc) cells without evidence of side effects [13].

These results, therefore, encouraged other groups to conduct new clinical trials involving RPE cells to treat different types of macular degenerations. However, there is a wide gap between the number of suitable RPE cells obtained from current production systems and the number required for implantation. In addition, commercial and large-scale production of cells for cell therapy protocols requires specific capabilities to develop technologies that will generate safe and effective cell lines [14].

Methods
Cell culture
The WA-09 embryonic stem cell lineage [15] was acquired directly from the Wicell Research Institute (WiCell, Madison, WI, USA) and thawed and cultured under current Good Manufacturing Practices (cGMP) conditions at the University of São Paulo (USP) Cell and Molecular Therapy Center (NUCEL) [16]. Pluripotent cell colonies were plated onto hESC-qualified Matrigel (Corning, NY, USA), maintained in mTeSR-1 medium (Stem Cell Technologies, Vancouver BC, Canada) and manually expanded every 4 to 5 days.

In vitro differentiation and RPE enrichment
Pluripotent WA-09 colonies were plated in six-well plates treated with Matrigel and the medium was renewed daily. To induce differentiation, the mTeSR-1 medium was replaced by serum-free X-VIVO 10 medium (Lonza, Walkersville, MD, USA) supplemented with Normocin (Invitrogen, San Diego, CA, USA), which was changed twice weekly.

For RPE enrichment, the areas with no pigmentation were removed manually from the plates using P200 tips under light phase microscopy. The remaining hESC-RPEs were dissociated with CTS TrypLE Select Enzyme (Invitrogen) for 5 min at 37 °C, passed through a 40-mm nylon cell strainer, counted, and seeded onto Synthemax Surface six-well plates (Corning) at 1.0 × 10e5 viable cells/cm². The hESC-RPEs were maintained in X-VIVO 10 medium and passaged with TrypLE every 30 to 35 days until passage three after enrichment.

Immunocytochemistry
hESC-RPE monolayers cultured adhered to coverslips were rinsed with Phosphate-buffered saline (DBPS) (Invitrogen) and fixed with 4% paraformaldehyde for 30 min at room temperature, blocked with 5% bovine serum albumin (BSA) and permeabilized with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) in DBPS for 1 h at room temperature. Primary antibodies, diluted in blocking solution, were incubated with the cells overnight at 4 °C.
Coverslips were rinsed three times with DPBS before the secondary antibodies diluted in blocking solution were added and then incubated for 1 h at room temperature. Cells were rinsed three times and 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) was added to the last wash. Slides were mounted with Vecta Shield Antifade Mounting Medium (Vector Laboratories, Burlingame, CA, USA) and images were acquired using the EVOS FL Imaging System (Thermo Fisher Scientific, Waltham, MA, USA). Antibodies: ZO-1 (Thermo Fisher), 1:100 and EZRN-1 (Novus Biologicals), 1:200.

Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific) with Power SYBR Green (Applied Biosystems, Foster City, CA). Total RNA was isolated using the Illustra RNAspin Mini Kit (GE Healthcare, Little Chalfont, UK), following the manufacturer’s instructions. Oligo-dT primed reverse-transcription was carried out using 2 µg of total RNA in 20 µl of RT reaction with SuperScript III (Invitrogen), followed by qPCR using 3 µl of the fivefold diluted RT reaction in 6 µl of PCR. Transcript levels were normalized to hydroxymethylbilane synthase (HMBS) and expressed as relative abundance using the delta Ct method [17]. Primer pairs (Table 1) were designed to create a 90 to 110 base pair product (Primer Express Software v3.0.1, Thermo Fisher Scientific).

Flow cytometry
Samples of hESC-RPE passage 3 were dissociated with CTS TrypLE Select Enzyme, washed with DPBS and fixed with 4% paraformaldehyde for 30 min at room temperature, blocked with 5% BSA, and permeabilized with 0.1% Triton X-100 in DPBS for 1 h at room temperature. Primary antibodies, diluted in blocking solution, were incubated with the cells for 1 h at room temperature. The cells were rinsed three times, 10 min each with DPBS, then incubated with the secondary antibody diluted in blocking solution for 1 h at room temperature. After incubation period, the cells were washed three times and analyzed in a BD Accuri C6 Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Antibody: Oct-4 (Cell Signaling), 1:200.

In vitro phagocytosis assay
hESC-RPE were tested for their phagocytic activity with the pHrodo Red E. coli Bioparticles® Conjugate kit (Thermo Scientific), following the manufacturer’s instructions. Briefly, the cells were cultured in 96-wells plates until confluence and then incubated with 100 µl of the above-mentioned particles for 2 h at 37 °C. After the incubation period, the plate was analyzed in a SpectraMax Paradigm Multi-Mode Microplate Reader (Molecular Devices, San Jose, CA, USA) (excitation, 560 nm and emission, 585 nm). Wells with particles but no cells or wells with cells but no particles were used as controls.

Results
The WA09 hESC lineage was thawed and expanded successfully at the NUCEL cGMP facility. These cells do not grow as single cells but, rather, as aggregates in colonies (Fig. 1). These colonies exhibited typical characteristics, i.e., homogeneous shape, smooth and regular edges, absence of regions of altered color, with cells presenting a high ratio of nucleus to cytoplasm (Fig. 2). The cultures were expanded manually by cutting each colony into small fragments, each of which would produce a new colony. The size of each fragment was about 200 × 200 µm (Fig. 1). After fragmentation, the small colonies were harvested gently with a cell scraper. Using these techniques, we maintained our culture growth as pluripotent cells, free from areas of undesired differentiation.

When the cultures reached 70% to 90% confluence, the cells were allowed to spontaneously differentiate into RPE by replacing the mTeSR-1 medium with serum-free X-VIVO 10 medium. Initially, a number of cells detached and died, but the remaining cells resumed growth, with recomposition of the cell monolayer.

At about 30 days after the start of differentiation, small pigmentation foci were observed (Fig. 2). These dark areas expanded and darkened for up 120 days, when the wells were ready for enrichment (Fig. 2).

Table 1 Sequence of primers used to monitor retinal pigment epithelial differentiation

| Primer   | Sequence                                      |
|----------|------------------------------------------------|
| hBEST1-RT-F | GCCGTGTCAGAGGATGACAA                           |
| hBEST1-RT-R | GCTGTACCCGCACAGTCA                           |
| hCRALBP-RT-F | CGAAGGTCTGCTTCAAA                            |
| hCRALBP-RT-R | CTCGCAAGATCTCATCAGAAAGGTGA                |
| hEZRN-RT-F | AATGCAGAACACATTGACATGT                     |
| hEZRN-RT-R | AGTTGTATTGCTTGATGACCA                       |
| hHMBS-RT-F | TGGACATGTGTGCTCATCCTCTTCTT                  |
| hHMBS-RT-R | CAACAGCATGACAGGACGGTTTCTTC                   |
| hPAX6-RT-F | CACCGGTTCCTCCTCCTAC                       |
| hPAX6-RT-R | TGCCAGACGGCCTGTAAGTGT                     |
| hRPE65-RT-F | CCTGCTGCAAGATTTGACCTTTAA                   |
| hRPE65-RT-R | GGAAAGCAGACGGTGCCAAATT                    |
| hZO1-RT-F | CACAGATCATCTGCTTGATGACCA                 |
| hZO1-RT-R | CCGGAGACTGCCATTGCT                         |
For enrichment, differentiated pigmented regions were isolated and the areas with no pigmentation were removed manually from the plates using a P200 tip (Fig. 3). The remaining hESC-RPEs were dissociated enzymatically, seeded onto the Synthemax Surface six-well plates and cultured for from 30 to 45 days, when the cells reacquired the epithelial shape and pigmentation and could be subjected to another round of enrichment. Usually, after the first round of enrichment, each well of the hESC-RPE cells yielded 3.10e6 cells, which could then be expanded to three new wells. This procedure was repeated up to three times until a homogenous cultures of hESC-RPE cells were achieved (Fig. 3). After 120 days of differentiation followed by 90 days of enrichment, our process resulted in a very pure population of hESC-RPE cells exhibiting the characteristic cobblestone shape and a high degree of pigmentation (Fig. 3).

To characterize the differentiated epithelium, samples were grown onto coverslips treated with Synthemax and then subjected to immunofluorescence labeling against typical mature RPE proteins, i.e., ZO-1 and Ezrin-1 (Fig. 4). Virtually all cells were positive for these RPE markers after differentiation and enrichment.

We also observed a progressive increase in the expression of the RNA levels of genes related to development of neuroectoderm and functionally mature RPE cells (Fig. 5), when the enriched cultures were compared to both undifferentiated WA09 cells and even to cultures in different stages of the differentiation process.

We then tested the functionality of these cells by measuring their ability to undergo phagocytosis. hESC-RPE cell monolayers were incubated in the presence of pHrodo E. coli Bioparticles® Conjugate for 2 h at 37 °C. After this incubation period, the samples were analyzed in a microplate reader. Even after a very short period,
Fig. 3  Enrichment for human embryonic stem cell-retinal pigment epithelium (hESC-RPE) cells. When the pigmented regions stopped expanding, the cultures were enriched. **a** The unpigmented areas are scraped off the plate and the remaining cells are passaged enzymatically to a Synthemax-treated well. **b** After up to three rounds of enrichment, the hESC-RPE cultures are homogenous, with purity exceeding 99%. **c** The typical high degree of pigmentation and cobblestone morphology of a hESC-RPE homogenous culture.

Fig. 4  Characterization of human embryonic stem cell-retinal pigment epithelium (hESC-RPE) cells by immunofluorescence. **a** DAPI. Fully differentiated hESC-RPE cells stained for **b** ZO-1 and **c** Ezrin-1. Bar: 200 microns.
more particles were internalized and processed by the differentiated cells than by the control samples (Fig. 6).

Finally, we investigated the presence of undifferentiated cells in the hESC-RPE cell final population. Fluorescence-activated cell-sorting analysis found that only 1.1% of the cells were positive for the Octamer-binding transcription factor 4 (OCT4) pluripotency marker (Fig. 7).

Discussion
Blindness severely impacts the quality of human life and is considered a significant economical and social burden worldwide. In the US, the total economic burden was estimated to be US$38.2 billion per year [18]. An even greater impact is evident in individuals younger than 40 years of age.

Since 1998, when James Thomson successfully cultivated hESCs for the first time these cells have been considered a valuable therapeutic tool. Their capacity for self-renewal and differentiation into other cell types...
make them perfect for use as an unlimited cell source for cell-based therapies [19]. Their therapeutic use has been proposed for treating several degenerative disorders, such as Parkinson’s disease [20], Alzheimer’s disease [21], muscular dystrophies [22], diabetes [23], and retinal degenerative diseases [24, 25]. In 2006, Takahashi and Yamanaka revolutionized the field with the advent of the induced pluripotent stem cells (iPSC) technology [26]. iPSCs are ideal for cell therapy protocols, since they can be generated specifically from each patient, which eliminates tissue rejection and the need for immunosuppression with its resultant side effects. iPSCs also may correct eventual mutations using genetic editing techniques [27].

The therapeutic use of suitable cells derived from human PSCs still poses an important challenge in cell therapy. To develop RPE replacement therapy, two key challenges must be addressed, i.e., the availability of healthy RPE cells for transplantation and a method of implantation. Several groups have reported that a synthetic substrate seeded with a monolayer of RPE cells may even increase graft survival [28–32]. Although pluripotent cell applications to treat retinal degenerative diseases are in high demand [33–35], it is necessary to elaborate and improve the differentiation protocols (Additional file 1) of these cells into RPE cells under cGMP conditions, using xeno-free or even animal-free compounds [28, 36].

The current study demonstrated that within a few months (4 months maximally), a large number of RPE cells were differentiated from an undifferentiated hESC lineage. This set of techniques favors the development of a cell therapy protocol for AMD that allows generation of a well-defined, well-characterized, readily available structure with no shortage problems. Our results showed that RPE cells differentiated in vitro behave similarly to mature RPE cells, since they express the same proteins displayed by adult RPE cells and also exhibit progressive expression of lineage-specific genes. In addition, using labeled bioparticles, we also showed their phagocytic activity, a characteristic function of these cells. Another important factor to consider is that the number of cells that still maintain pluripotency markers at the end of the protocol is extremely low when compared to similar protocols from another group [37]; this represents great safety in the possible clinical applications of these cells, since the risk of tumorigenesis is strongly related to the number of contaminated pluripotent cells in the culture. In fact, in our pre-clinical experiments, no tumor formation occurred [30].

The clinical translation of RPE cells requires a scalable expansion bioprocess for manufacturing of therapeutically qualified cells. Generally, after the first round of enrichment, each well of hESC-RPE yielded 3.10^6 cells, which can be expanded to three new wells, without diminishing the cellular differentiative status. Therefore, a full six-well plate of hESC-RPE cells at passage 0 can yield up to nine plates at the end of the third round of enrichment or 1.6 × 10^8 cells. According to experimental data from groups already using PSC-derived RPE cells in clinical protocols, this amount of cells would be sufficient to treat more than 1000 degenerated retinas. Based on the growing number of patients diagnosed annually, other methodologies are being proposed to even increase cell production at both lower cost and risk of contamination compared to the conventional monolayer.
In conclusion, our results demonstrated the establishment of a serum-free, feasible, and secure protocol to derive functional RPE cells from human PSCs, with minimal manipulation. Although the costs of production remain high and only a few centers have the technical capacity and trained personnel needed to derive and expand these cells, the RPE implant derived from PSCs offers the greatest promise for treating a disease that still lacks an effective treatment.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s40942-019-0194-7.

Acknowledgements

We would like to thank Dennis Clegg from the University of California, Santa Barbara, CA, USA, and Mark S. Humayun, from the University of Southern California, Los Angeles, CA, USA.

Authors’ contributions

FHL and RAB contributed equally to this work, designing and executing the experiments, and preparing the manuscript. FHL offered technical support, CEF and PC helped to design the experiments and revised the manuscript. MM, MCS, and RBJ followed the development of this work, discussed the results, and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Brazilian Research and Development Council (Conselho Nacional de Desenvolvimento Científico e Tecnológico), Grant no. 400036/2013-4, in addition to the Science and Technology Ministry and the Health Ministry. The authors acknowledge the collaboration of Professor Dennis Clegg (Center for Stem Cell Biology and Engineering) for assistance and the technical support of NUCEL-USP.

Availability of data and materials

The authors declare that all data supporting the findings of this study are available within the article.

Ethics approval and consent to participate

This study was performed in accordance with the Declaration of Helsinki and was approved by two Ethical committees, the Ethical Research Committee (NUCEL), Medical School, University of São Paulo, CEP 04021-001 São Paulo, Brazil.

Consent for publication

All authors provide consent to publication of this study, “In vitro differentiation of cGMP-grade retinal pigmented epithelium from human embryonic stem cells,” in the International Journal of Retina and Vitreous.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, CEP 04021-001 São Paulo, Brazil. 2 Cell and Molecular Therapy Center (NUCEL), Medical School, University of São Paulo, São Paulo, SP 05360-130, Brazil. 3 Department of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, SP 05508-000, Brazil. 4 Department of Orthopedics and Traumatology, Federal University of São Paulo, São Paulo 04038-032, Brazil.

References

1. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.
2. Pascolini D, Mariotti SP. Global estimates of visual impairment 2010. Br J Ophthalmol. 2012;96:614–8. https://doi.org/10.1136/bjophthalmol-2011-300539.
3. Bressler NM, Bressler SB, Condon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121:1621–4.
4. Reim DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009;127:533–40.
5. Bressler SB, Bressler NM. Age-related macular degeneration: non-vascular early AMD, intermediate AMD, and geographic atrophy. Ryan Retina. 5th ed. New York: Elsevier; 2012.
6. McLeod DS, Grebe R, Bhutto I, et al. Relationship between RPE and choriodoipillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:4982–91.
7. Lu B, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells. 2009;27:2126–35.
8. Lund RD, et al. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells. 2006;8:189–99.
9. Schwartz SD, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379:713–20.
10. Schwartz SD, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509–16.
11. Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium for the treatment of macular degeneration: an assessment at 4 years. Invest Ophthalmol Vis Sci. 2016. https://doi.org/10.1167/iovs.15-18681.
12. Song WK, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Reports. 2015;4:860–72.
13. Mandal M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376:1038–46.
14. Abbashalizadeh S, Pakzad M, Cabral JMS, Baharvand H. Allogeneic cell therapy manufacturing: process development technologies and facility design options. Exp Opin Biol Ther. 2017;17:1201–9.
15. Thomson JA, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–7.
16. Colin C, Demasi MA, Degaki TL, et al. NUCEL (Cell and Molecular Therapy Center): a multidisciplinary center for translational research in Brazil. Mol Biotechn. 2008;39:89–95.
17. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucliec Acids Res. 2001;29:e43.
18. Wittenborn JS, Zhang X, Feagan CW, et al. The economic burden of vision loss and eye disorders among the United States population younger than 40 years. Ophthalmology. 2013;120:1728–35.
19. Klimanskaya I, Rosenthal N, Lanza R. Derive and conquer: sourcing and differentiating stem cells for therapeutic applications. Nat Rev Drug Discov. 2008;7:131–42.
20. Cho MS, Lee Y-E, Kim JY, et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA. 2008;105:3392–7.
21. Tong LM, Fong H, Huang Y. Stem cell therapy for Alzheimer’s disease and related disorders: current status and future perspectives. Exp Mol Med. 2015;47:e151.
22. Goudenege S, et al. Myoblasts derived from normal hESCs and dystrophic hPSCs efficiently fuse with existing muscle fibers following transplantation. Mol Ther. 2012;20:2153–67.
23. Rezania A, Bruin JE, Arora P, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32:1211–33.
24. Binder S, Stanzel BV, Krebs I, Glittenberg C. Transplantation of the RPE in AMD. Prog Retin Eye Res. 2007;26:516–54.
25. Idelson M, Alper R, Obolensky A, et al. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell. 2009;5:396–408.
26. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.
27. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–21.
28. Pennington BO, Clegg DO. Pluripotent stem cell-based therapies in combination with substrate for the treatment of age-related macular degeneration. J Ocul Pharmacol Ther. 2016;32:261–71.
29. Hu Y, Liu L, Lu B, et al. A novel approach for subretinal implantation of ultrathin substrates containing stem cell-derived retinal pigment epithelium monolayer. Ophthalmic Res. 2012;48:186–91.
30. Brant Fernandes RA, Koss MJ, Falabella P, et al. An innovative surgical technique for subretinal transplantation of human embryonic stem cell–derived retinal pigment epithelium in Yucatan mini pigs: preliminary results. Ophthalmic Surg Lasers Imaging Retina. 2016;47:342–51.
31. Diniz B, Thomas P, Thomas B, et al. Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer. Invest Ophthalmol Vis Sci. 2013;54:5087–96.
32. Thomas BB, Zhu D, Zhang L, et al. Survival and functionality of hESC–derived retinal pigment epithelium cells cultured as a monolayer on polymer substrates transplanted in RCS rats. Invest Ophthalmol Vis Sci. 2016;57:2877–87.
33. Nazari H, Zhang L, Zhu D, et al. Stem cell based therapies for age-related macular degeneration: the promises and the challenges. Prog Retin Eye Res. 2015;48:1–39.
34. Westenskow PD, Kurihara T, Friedlander M. Utilizing stem cell-derived RPE cells as a therapeutic intervention for age-related macular degeneration. Adv Exp Med Biol. 2014;801:323–9.
35. Fields M, et al. Potential of induced pluripotent stem cells (iPSCs) for treating age-related macular degeneration (AMD). Cells. 2016;5:5.
36. Leach LL, Clegg DO. Concise review: making stem cells retinal: methods for deriving retinal pigment epithelium and implications for patients with ocular disease. Stem Cells. 2015;33:2363–73.
37. Buchholz DE, Pennington BO, Croze RH, Hinman CR, Coffey PJ, Clegg DO. Rapid and efficient directed differentiation of human pluripotent stem cells into retinal pigment epithelium. Stem Cells Transl Med. 2013;2:384–93.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.